Kornimate/medical-research-clean huggingface dataset:
the study of hemp oil cbd for evaluation of efficacy and safety in treatment of pain, anxiety and insomnia management

Conditions: CBD; Pain, Chronic; Anxiety; Insomnia; Opioid Use

Summary: the investigators are looking to conduct a study looking at the effects of cannabidiol (cbd) from hemp oil in patients with chronic pain, anxiety and insomnia. it is believed that cbd will improve pain anxiety and sleep quality and reduce opioid use. the study will last a total of 4 weeks and involve onsite visits in addition to weekly pain assessments.

the proposal is to conduct a interventional cohort pilot study to evaluate the effectiveness of cbd on the management of chronic pain, anxiety and insomnia. subjects will be pre-screened from new and existing patients as well as from referral sites for the diagnosis of chronic pain. potential subjects will be screened for pain \>3 months who are using oral analgesic including narcotics and or physical therapy to reduce pain. those meeting all inclusion and exclusion criteria will receive a comprehensive history and physical exam and undergo informed consented at the screening visit. baseline survey data will be collected including various pain rating surveys. the patient's will be monitored for compliance to complete the weekly rating using a research phone application. subjects will receive either cbd tincture or cbd topical cream.this will be dosed daily for a total of 4 weeks. patients will be evaluated on three pain rating scales: on initial evaluation and 4th week evaluation, patients will be asked to fill out the brief pain inventory and pain disability index. once weekly, a numeric rating scale. on initial evaluation and at 4th week evaluation, narcotic dosing will be reviewed and recorded. quality of sleep and anxiety scale will also be recorded for the four weeks using the hamilton anxiety scale and sleep quality assessment at the start and end of the 4 weeks. at initiation and conclusion of study blood work to evaluated levels of cbd in each patient. subjects will be screened for side effects as well as records of pain medication use throughout the duration of the study

Eligibility criteria:
inclusion criteria: * patients with pain \>3 months who are using oral analgesic including narcotics and or physical therapy to reduce pain. * patient provides informed consent * older than 21 years old, * previously have used cbd or marijuana * speaks english exclusion criteria: * patients who are receiving interventional pain procedures or surgery within 30 days * for their pain * patients who have had pain \<3 months * presence of serious medical illness * pregnant females * use of p450 modifying medications.
allogeneic human umbilical cord mesenchymal stem cells for a single male patient with duchenne muscular dystrophy (dmd)

Conditions: Duchenne's Muscular Dystrophy

Summary: this research study is designed to evaluate the effects of human umbilical cord mesenchymal stem cells (uc-mscs), on duchenne's muscular dystrophy (dmd). the potential muscle regenerative and anti-inflammatory properties of uc mscs position them as a possible treatment option for dmd. both of these properties could lead to potential benefits for a dmd patient.


Eligibility criteria:
inclusion criteria: * duchenne's muscular dystrophy exclusion criteria: * none

Keywords: mesenchymal stem cells umbilical cord duchenne's muscular dystrophy
postoperative chewing gum and gynecological laparoscopic surgery

Conditions: Gynecologic Disease; Postoperative Ileus; Paralytic Ileus

Summary: the authors aimed to evaluate the effects of postoperative gum chewing on laparoscopic gynecological surgery, gastrointestinal function-intestinal mobility and early postoperative recovery. patients undergoing elective gynecological laparoscopy were randomized. demographic and characteristic features of the patients were recorded. operation type, operation and anesthesia information were recorded. patients underwent a postoperative routine regimen. starting from the sixth hour, the sugar-free gum was crushed every 15 minutes until the gas was released. postoperative follow-up was performed routinely. the first bowel movements, first bowel movements and first gas extraction and first decongestation periods were recorded.

the team of the research team of the research team will listen and record the bowel sounds of the patients, using a stethoscope every two hours starting from the postoperative 3rd hour until the first bowel sounds are heard in each patient. patients who were able to tolerate patients starting from the 8th hour after the surgery were allowed for mobilization. also, they were allowed to take fluid regimen from the postoperative 12th hour. patient satisfaction was evaluated by using visual analogue scale (vas) on the day of discharge on chewing postoperative. the primary index for the return of gi functions was the first gas removal time. secondary index was the time of first bowel sound, the first time of admission, hospitalization time and the presence of postoperative ileus.

Eligibility criteria:
inclusion criteria: * patients undergoing elective laparoscopic gynecological surgery. exclusion criteria: * those who have been operated for malignant reasons, * those who underwent emergency surgery, * who could not chew gum, * who had serious surgical complications (postoperative intraabdominal hemorrhage, infection, peritonitis), * who had a history of gastrointestinal disease, * secondary laparotomy.

Keywords: laparoscopic surgery postoperative bowel function
"evaluation of the effectiveness of the mdt method (mechanical diagnosis and therapy) in the management of low back pain in the subacute phase"

Conditions: Low Back Pain

Summary: the investigators propose to carry out a study evaluating the effectiveness of the mdt method (mechanical diagnosis and therapy) in the subacute phase of common low back pain. few studies have specifically evaluated the effectiveness of the mdt method in the subacute phase, a phase that appears to be crucial before the chronicization of low back pain. the main objective of this study will be to evaluate the pain of patients managed by the mdt method. the analysis of the main criterion (visual analog scale) will be done using a type individual clinical trial specific: the single case experimental design or sced in lines of multiple bases. this type of study makes it possible to carry out a comparative test on a single subject acting as its own witness in order to obtain an acceptable level of evidence response for that particular patient.


Eligibility criteria:
inclusion criteria: * consultant patients at the picasso physiotherapy practice (5 rue nina simone - 44 000 nantes) * aged 18 to 55 years old * suffering from common-looking low back pain. low back pain is defined as pain or localized discomfort under the 12th dorsal vertebrae and above the inner fold buttock, with possible irradiation to the lower limb but not exceeding the knee. * evolving for 4 to 12 weeks (subacute period). * period preceded by a period of 30 days without low back pain (in order to avoid recurrent low back pain, rather similar to the chronic phase). exclusion criteria: * signs of specific low back pain (confirmed or highly suspected diagnosis): fracture, infection, osteoporosis, inflammatory disease, tumor * irradiation below the knee * patient knowing she is pregnant * protected adults * patient with proven cognitive impairment * patient with a decompensated psychiatric pathology * incapacity to consent * refusal to participate in the study
pdl-1 expression on circulating tumor cells in non-small cell lung cancer

Conditions: Lung Cancer

Summary: immunotherapy is probably, since the development of therapies targeting egfr mutations or alk rearrangement, the most attractive therapeutic perspective in the management of metastatic lung cancer. among the compounds tested, the inhibitors of the immune checkpoint programme death 1 / programme death ligand 1 (pd-1/pd-l1) have been tested in numerous clinical trials with recently published positive results leading to the approval of one drug in the usa and an expanded access program for two drugs in france. programme death ligand 1 (pd-l1) expression by tumor cells is strongly associated with the response to such molecules so that the participation in various clinical trials is currently reserved for patients expressing this biomarker and therefore justifies a new invasive biopsy (bronchoscopic or ct-guided) representing a considerable drag on the access to these treatments. circulating tumor cells (ctcs) isolated by isolation by size of tumor cells (iset) offer a direct and non-invasive access to the tumor. it has already been demonstrated that molecular characterization (egfr, alk) on these blood samples is possible. we propose to demonstrate the feasibility of the analysis pdl-1 expression in these cells by immunocytochemistry. myeloid-derived suppressor cells (mdscs) are immature myeloid cells that inhibit t cell functions and thus promote tumor growth. these cells frequently express pd-l1. we propose to test whether mdscs level and its evolution during treatment with pd1 inhibitor is correlated to the response to these drugs. the main objective of this study is to demonstrate the feasibility of the analysis of pd-l1 expression on ctc


Eligibility criteria:
inclusion criteria: * stage iv non-small cell lung cancer patient prior to start immunotherapy treatment * patients with world health organization (who) performance status 0-3 * patients who were informed and had non opposition form signed by investigator * patients with healthcare insurance system affiliation exclusion criteria: * prior malignancy within 5 years of study entry * refusal to participate * patient under legal protection

Keywords: pd-1/pd-l1 immune checkpoints immunotherapy lung cancer circulating tumor cells immunocytochemistry iset mdsc stage iv non-small cell lung cancer
post intensive care syndrome in covid19 patients

Conditions: COVID19; Post Intensive Care Unit Syndrome

Summary: this project is based in the implementation of a combined monitoring system (technological solutions and medical visits) in survivors of the critical illness due to the infectious disease by covid-19. the main objective of the project is to characterize the post-intensive care syndrome (pics) and detect early needs for specific treatment.


Eligibility criteria:
inclusion criteria: * patients admitted to icu for covid 19 exclusion criteria: * mental health diagnosis previous to the covid19 infection * acquired brain damage or neurological disease previous to the covid19 infection
safety and preliminary efficacy of mk0759 in postherpetic neuralgia (phn)(0759-004)

Conditions: Neuralgia, Postherpetic

Summary: the purpose of this study is to test the safety and effect of mk0759 in relieving neuropathic pain as experienced by patients with postherpetic neuralgia (phn).


Eligibility criteria:
inclusion criteria: * age 18 to 85; diagnosis of postherpetic neuralgia with pain having persisted at least 6 months; dissatisfied with current regimen of pain control; able to complete study questionnaires, patient diary, and comply with daily study medication exclusion criteria: * women of childbearing potential; history or evidence of a condition that, in the opinion of the investigator, may interfere with the study interpretation (e.g., diabetic neuropathy or fibromyalgia) or pose undue risk to undergo the course of medication required by the study (e.g., unstable heart disease, morbid obesity, kidney or liver disease).
direct acting agents in hepatitis c patients

Conditions: Hepatitis C; Hepatitis C Relapse; Hepatitis C Recurrent

Summary: this study is a retrospective study conducted at 36 sites. planned target patient number is 1000.

approximately 36 centers will be included in turkey. centers will be selected from clinics of infection and clinical microbiology. the inclusion of 1000 patients was targeted. all data will be retrospectively collected from the medical records of the patients. patient visit is not necessary.

Eligibility criteria:
inclusion criteria: * patients who used direct acting agents for hepatitis c exclusion criteria: * patients younger then 18 years

Keywords: daa hepatitis
the effect of dpp4 inhibitor on vasclular healing

Conditions: Acute Coronary Syndrome; Diabetes Mellitus, Type 2

Summary: this study evaluate the effect of dipeptidyl-peptidase 4 inhibitor on vascular healing after biodegradable polymer based sirolimus eluting stent implantation in diabetic pateints.


Eligibility criteria:
inclusion criteria: * non-st segement elevation acute coronary syndrome exclusion criteria: * left main disease * known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, sirolimus, siptagliptin and statin * congestive heart failure (patients with lvef \<30% or cardiogenic shock) * uncontrolled myocardial ischemia (repeated chest pain or dyspnea after revascularization) * uncontrolled ventricular arrhythmia * history of malignancy with chemotherapy * serious hematologic disease (e.g. cml, mds) * current infectious disease needs antibiotics therapy * creatinine level \>1.5 mg/dl or dependence on dialysis * other severe concurrent illness (e.g. active infection, malignancy). * life expectancy of less than one year * pregnancy or women with potential childbearing * type i dm * treatment with insulin * history of pancreatitis * who cannot read the informed consent form (e.g. illiteracy, foreigner)
safety and tolerability of shr-1918 in healthy subjects

Conditions: Hyperlipemia

Summary: the primary objective of this study is to assess the safety and tolerability of shr-1918 injection in healthy subjects. in addition, this study will provide information on pharmacokinetics and pharmacodynamics of shr-1918 injection in healthy subjects.


Eligibility criteria:
inclusion criteria: 1. age ≥18 and ≤65 on the date of signing the informed consent, males or females; 2. 1.7 mmol/l≤tg≤5.6 mmol/l，2.6 mmol/l≤ldl-c\<4.9 mmol/l; 3. understand the study procedures and methods, volunteer to participate in the study, and sign the informed consent. exclusion criteria: - 1.history of disease or treatment for: 1. known allergic reaction to experimental drugs or severe allergic reaction to other antibody drugs; 2. malignncy; 3. combined cardiovascular, hepatic, renal, gastrointestinal, neuropsychiatric, hematological, or metabolic diseases; 4. history of any drug use prior to screening or within 2 weeks prior to baseline 2.any one of the following tests at screening : 1. alanine aminotransferase (alt) or aspartate aminotransferase (ast) or gamma-glutamyl transferase (ggt) exceeding 2 times uln, or total bilirubin exceeding 1.5 times uln 2. creatine kinase (ck) exceeding 3 times the upper limit of normal (uln) 3.general: 1. history of drug or substance abuse; 2. average of 5 or more cigarettes per day during the 4 weeks prior to screening; 3. history of blood donation within 3 months prior to screening, or severe blood loss (≥400 ml blood loss), or received a blood transfusion within 4 weeks; 4. vaccination within 2 weeks prior to screening or planned during the course of the trial 4.the investigator determines that the subjects have poor compliance or have any factors that may prevent them from participating in the study, including, but not limited to, the study placing the subjects at unacceptable risk or possibly interfering with the study results.
complications from the use of calcium phosphate paste in mandibular lengthening osteotomies

Conditions: Jaw Anomalies; Infection

Summary: the goal of this study is to determine if the use of calcium phosphate paste in mandibular lengthening surgery causes more complications as surgical site infections and hardware removal. an evaluation will be made to determine if the benefits of the use of the paste (3d-stability, prevention of early relapse and unaesthetic indentation) outweighs the disadvantages.

the sagittal split osteotomy (sso) is commonly used to correct dentofacial discrepancies. correction of distocclusion can be achieved through lengthening of the mandible, and a balanced facial appearance can be obtained by increasing chin projection. calcium phosphate paste is used in mandibular lengthening surgery to avoid an unaesthetic notching at the lower border(1)(2) and to help stabilize the segments when osteosynthesis slippage is feared for. a recently performed retrospective study showed an increase of infectious complications when calcium phosphate paste was used for this indications. several precautions were identified that could be undertaken to decrease the infectious complications. the study concluded that a prospective study was required in which these precautions were implemented to determine whether infectious complications can be reduced. the aim of this study is to investigate whether the hardened paste still increases the incidence of site infections after implementation of several precautions and the use of a standardized antibiotic prophylactic protocol.

Eligibility criteria:
inclusion criteria: * all patients with dysgnatic deformities requiring mandibular lengthening surgery * gender: m/f * age: \>15y-75y exclusion criteria: * previous orthognathic surgery * congenital facial malformations * unilateral sso * immunodeficiency * simultaneous removal of lower third molars * incomplete postoperative follow-up

Keywords: calcium phosphate paste
application of eras protocol in emergency surgery

Conditions: Enhanced Recovery After Surgery; Emergency Surgery

Summary: this study defines a standardized protocol inspired to the eras philosophy for the peri-operative treatment of patients undergoing emergency abdominal surgery. primary endpoint is the feasibility of the application of the standardized protocol; secondary endpoint is the safety


Eligibility criteria:
inclusion criteria: * patients undergoing emergency abdominal surgery for abdominal sepsis or occlusion and treated with bowel resection with or without anastomosis, intestinal bypass or adhesiolysis. exclusion criteria: * age \<18 * emergency surgery for post-operative complications of post diagnostic procedures
does weight loss surgery and probiotic supplementation lead to a "lean" gut microbiota?

Conditions: Obesity

Summary: the purpose of the weight-loss study is to characterize the effect of lgg supplementation on the relative abundance of phyla in the gut microbiota of patients undergoing gastric bypass and sleeve gastrectomy surgery, and to elucidate a relationship between the gut microbiota pattern and the degree of weight-loss post-surgery. the investigators hypothesize that lgg administration will result in a "leaner" pattern of gut microbiota that will lead to higher weight loss at 3 months post-surgery.


Eligibility criteria:
inclusion criteria: 1. age greater than or equal to 18 years 2. able to give informed consent and report on side effects 3. tolerating an oral/enteral diet 4. stable comorbid conditions 5. outpatient exclusion criteria: 1. inpatients 2. pregnancy (urine test done on all patients routinely pre-op)/ unwilling to comply with contraceptive requirement after gastric bypass surgery 3. known use of lgg or another probiotic (not including yogurt) within the previous 30 days 4. presence of an active bowel leak, acute abdomen, active intestinal disease, or significant bowel dysfunction 5. presence of an absolute neutrophil count less than 500 per cubic mm (must have had a complete blood count within the last 6 months) or anticipation post chemotherapy that the absolute neutrophil count will fall below 500 per cubic mm. 6. history of adverse reaction to product containing lactobacillus 7. active colitis (\*see definition below) 8. known or suspected allergies to probiotics, lactobacillus, milk protein, or microcrystalline cellulose 9. structural heart disease, history of endocarditis or valve replacement, implanted cardiac device, congestive heart failure 10. positive baseline stool culture for lgg 11. recent or planned chemotherapy or radiation therapy 12. solid organ transplant within the prior year 13. stem cell transplant within the prior year 14. on active immunosuppressive medication \[anti-rejection, injectable immunosuppressive drugs for autoimmune disease, or corticosteroids (greater than ½ mg per kg body weight of prednisone or its equivalent) not including inhaled or topical steroids\] 15. allergy or intolerance to or contraindication to two or more of the rescue antibiotic regimens (ampicillin, clindamycin, moxifloxacin) 16. participating in another clinical trial 17. uncontrolled psychiatric illness

Keywords: gastric bypass microbiota probiotic
integrative medicine for chronic pain

Conditions: Chronic Pain

Summary: in this study, the effects of a 14-day inpatient treatment in an internal medicine ward for integrative medicine on pain, disability, quality of life, satisfaction with life, depression, and anxiety will be investigated. furthermore the influence of potential process variables will be evaluated. effects will be measured after completion of the program (2 weeks), and at 6 months follow up after start of the program.


Eligibility criteria:
inclusion criteria: * diagnosed with any chronic pain condition * at least 6 months pain duration * written informed consent exclusion criteria: * participation in any other clinical study
depression study in elderly patients

Conditions: Depressive Disorder, Major; Major Depressive Disorder (MDD)

Summary: major depressive disorder (mdd) study in elderly outpatients


Eligibility criteria:
inclusion criteria: * diagnosis of major depressive disorder (mdd). * current major depressive episode at screen at least 2 months duration. * must be at least 60 years of age. exclusion criteria: * patients with a primary diagnosis other than mdd. * patients with a history of schizophrenia, schizoaffective disorder, bipolar disorder or dementia. * patients with a history of brief depressive episodes lasting less than 8 weeks. * patients receiving formal psychotherapy within 12 weeks of study. * patients who are suicidal. * patients who have received electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior to screening. * patients with a history or seizure disorders.

Keywords: elderly major depressive disorder mdd